ProCE Banner Activity

VIALE-A: Extended Follow-up of Azacitidine ± Venetoclax in Patients With Treatment-Naive AML Ineligible for Standard Induction Chemotherapy

Slideset Download
Conference Coverage

Venetoclax + azacitidine showed ongoing OS benefit vs azacitidine monotherapy in patients with newly diagnosed AML ineligible for intensive chemotherapy with an additional 2 years of follow-up.

Released: December 17, 2022

Expiration: December 16, 2023

No longer available for credit.

Share

Provided by

Provided by Clinical Care Options, LLC

ProCE Banner

Supporters

AbbVie

Amgen

AstraZeneca

Epizyme

GSK

Incyte Corporation

Jazz Pharmaceuticals

Karyopharm Therapeutics Inc.

Novartis Pharmaceuticals Corporation

Sanofi

Seagen